Valvular & structural heart disease
Transcatheter Treatment of Native Aortic Valve Regurgitation: The North American Experience With a Novel Device
Authors' conclusion
The J-Valve appears to provide a safe and effective alternative to surgery in patients with pure AR and elevated or prohibitive surgical risk.
Study context
- Population
- Patients with severe symptomatic native AR and elevated surgical risk, North America, 2018–2022
- Participants
- 27 patients
- Outcome
- Procedural success (delivered to intended location without surgical conversion or a second transcatheter heart valve)
Methodological detailsmulticentre, compassionate use
- Multicentre
- Compassionate use
Main finding
As reported in the abstract
| Group | Value | Last 15 cases |
|---|---|---|
| J-Valve | 81% | 100% |
J-Valve
Value81%
Last 15 cases100%
Observational data: associations, not effects.
Further findings
Procedural success, last 15 cases
- Procedural success in the last 15 cases
- 100%
NYHA class I or II · 30 days
- Patients in NYHA class I or II
- 88%
Residual AR of moderate or greater degree · 30 days
- No patient had residual AR of moderate or greater degree
Death, stroke, new pacemaker · 30 days
- Death
- 1
- Stroke
- 1
- New pacemakers
- 3 (13%)
Safety
- Cases requiring conversion to surgery in the early experience
- 2
- Led to changes in valve design
Original publication
Transcatheter Treatment of Native Aortic Valve Regurgitation: The North American Experience With a Novel Device. JACC Cardiovasc Interv. Published 17 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →